The COMBAT-PsA trial, sponsored by NHS Greater Glasgow and Clyde in collaboration with Eli Lilly and the University of Glasgow, aims to explore the synergistic effects of Tirzepatide and Ixekizumab in treating Psoriatic Arthritis (PsA) in patients with obesity. The trial's focus on the molecular changes in skin, joint, and fat tissues, alongside weight loss, positions it strategically within the growing market for PsA therapies, particularly as obesity is increasingly recognized as a significant comorbidity. The results could provide valuable insights into the dual therapeutic approach, potentially enhancing the commercial viability of both Tirzepatide and Ixekizumab. Given the competitive landscape, successful outcomes may lead to expanded indications for these agents, thereby increasing their market share and addressing unmet needs in PsA management.